middle.news
Actinogen’s XanaMIA Trial Clears Third Safety Review Ahead of November Results
8:57am on Thursday 18th of June, 2026 AEST
•
Biotechnology
Read Story
Actinogen’s XanaMIA Trial Clears Third Safety Review Ahead of November Results
8:57am on Thursday 18th of June, 2026 AEST
Key Points
Third positive Data Monitoring Committee safety recommendation
247 patients enrolled with over 100 treated for 36 weeks
Xanamem 10 mg daily shows promising safety profile
Trial assesses slowing of Alzheimer’s progression via CDR-SB endpoint
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE